What are the causes of gallbladder polyps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Gallbladder Polyps

Gallbladder polyps are broadly caused by two distinct pathologic processes: nonneoplastic lesions (primarily cholesterol deposition and inflammation) and neoplastic lesions (including benign adenomas and malignant carcinomas), with the vast majority being benign cholesterol polyps related to lipid metabolism abnormalities. 1

Pathologic Classification and Etiology

Nonneoplastic Polyps (Most Common)

The majority of gallbladder polyps are nonneoplastic, accounting for approximately 94% of all polyps 1:

  • Cholesterol polyps (most common type): Result from cholesterol deposition in the gallbladder mucosa, strongly linked to lipid metabolism disorders 2
  • Inflammatory polyps: Arise from chronic inflammation of the gallbladder wall
  • Adenomyomatosis: Represents mural hyperplasia with intramural cholesterol crystals 1

These nonneoplastic polyps are typically smaller (mean size 4-7.5 mm) and carry negligible malignancy risk 1.

Neoplastic Polyps (Rare but Clinically Significant)

Only 6% of gallbladder polyps are neoplastic 1, including:

  • Intracholecystic papillary neoplasms (ICPNs): Mass-forming epithelial neoplasms ≥10 mm with varying degrees of dysplasia
  • Pyloric gland adenomas: Occur in 0.2-0.5% of cholecystectomy specimens, may be associated with familial adenomatous polyposis or Peutz-Jeghers syndrome 1
  • Adenocarcinomas: Rare malignant transformation

Neoplastic polyps are typically larger (mean size 18-21 mm) 1.

Risk Factors for Polyp Formation

Metabolic and Lipid-Related Factors

Cholesterol polyps are closely tied to lipid metabolism abnormalities 2:

  • Age >50 years (OR 3.02) - strongest independent risk factor 2
  • Elevated LDL cholesterol >2.89 mmol/L (OR 1.38) 2
  • Low HDL cholesterol (OR 1.78) - significant protective effect when normal 2, 3
  • Elevated AST >40 IU/L (OR 3.55) 2
  • BMI >25 kg/m² (OR 1.32) 2
  • Dyslipidemia and obesity 4

The pathogenesis involves supersaturated bile with cholesterol crystals precipitating in the gallbladder mucosa 5.

Genetic and Geographic Factors

Geographic and ethnic variations suggest underlying genetic influences 1:

  • Highest incidence in North and South American Indigenous populations (up to 23 cases per 100,000 for women)
  • Elevated rates in North Indian, Japanese, and Hispanic American populations (up to 7.5 cases per 100,000) 1
  • Male sex increases risk (OR 0.646) 6
  • Familial GBC with possible maternal transmission (standardized incidence ratio 5.21) 1
  • Family history of gastrointestinal disease 3

Infectious and Inflammatory Factors

  • Hepatitis B virus infection (OR 1.113) - significant association in Chinese populations 6
  • Chronic hepatitis C virus infection 4
  • Primary sclerosing cholangitis (PSC) - creates biliary epithelium field defect with 18-50% association with malignancy in polyps 1
  • Salmonella typhimurium infection 4

Other Biological Mechanisms

The development of malignant polyps is regulated by 4:

  • Hormone levels in vivo
  • Gut microbiota alterations
  • Chronic inflammation and oxidative stress
  • Liver function abnormalities

Clinical Pearls and Caveats

Important distinction: Most gallbladder cancers do NOT manifest as polyps, so patient risk factors for overall gallbladder cancer may not directly extrapolate to polyp malignancy risk 1. The key clinical concern is differentiating malignant polyps from both benign neoplastic and nonneoplastic polyps.

Natural history: Small polyps (<10 mm) have a benign natural history, with 91% showing no change over 5 years and 46% becoming undetectable on follow-up 5, 7. The rate of malignant transformation is extremely low 1.

PSC exception: Standard guidelines should NOT be applied to patients with PSC due to dramatically elevated malignancy risk; refer to specialty gastroenterology guidelines 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.